Improved overall survival was found in patients with smaller tumors (T1 + T2) (adjusted P = 0.003), absence of lymph node metastases (adjusted P = 0.041), no recurrences (adjusted P = 0.0001), higher Tregs counts (adjusted P = 0.035), and lower CD8+/Tregs ratio (adjusted P = 0.011). The gene discussed is CD8A; the disease is metastatic malignant neoplasm in the lymph nodes.